Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02646748. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors
Study identification
- NCT ID
- NCT02646748
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Interventions
- INCB050465 Drug
- Pembrolizumab Drug
- itacitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2016
- Primary completion
- Nov 6, 2019
- Completion
- Nov 19, 2020
- Last update posted
- Mar 30, 2022
2016 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| John Wayne Cancer Institute at Providence Saint John's Health Center | Santa Monica | California | 90404 | — |
| Georgetown University Medical Center Lombardi CCC | Washington D.C. | District of Columbia | 20007 | — |
| Hematology-Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 37952 | — |
| Emory University, Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Kentucky, Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision) | Bethesda | Maryland | 20817 | — |
| Beth Israel Medical Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital System | Detroit | Michigan | 48202 | — |
| St. Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| UPMC CancerCenters, Hilman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| HOPE Cancer Center of East Texas | Tyler | Texas | 75701 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02646748, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2022 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02646748 live on ClinicalTrials.gov.